Evidence on brain cancer and hematological malignancies after radiation exposure from pediatric CT scans



Prof. Dr. Michael Hauptmann michael.hauptmann@mhb-fontane.de Institute of Biostatistics and Registry Research



Computed tomography: frequency & dose



In US per year

- 23m (1993), 70m (2007), 93m (2023)
- 3m (~3%) in children in 2023, including 1.6m head CTs

| Table 1. Typical Organ Radiation Doses from Various Radiologic Studies. | | | | | |
|---|-------------|-----------------|------|--------------------------------------|----|
| Study Type | | levant Irgan | | Relevant Organ Dose* (mGy or mSv) | |
| Dental radiography | | Brain | | 0.005 | |
| Posterior-anterior chest radiography | | ung | | 0.01 | |
| Lateral chest radiography | | ung | | 0.15 | |
| Screening mammography | | reast | | 3 | |
| Adult abdominal CT | Sto | omach | | 10 | |
| Barium enema | C | olon | | 15 | |
| Neonatal abdominal CT | Sto | omach | | 20 | |
| Pediatric head CT | | Brain | | | 46 |
| Pediatric head CT | Bone marrow | | w 12 | | 12 |
| Pediatric abdomen/pelvis CT | Bone | ne marrow | | 8 | |

Smith-Bindman et al, JAMA Int Med 2025


~100,000 pediatric CTs 2015-2020 from UCSF Int'l CT Dose Registry

Chu et al, Rad Res 2025

Large studies with dosimetry




nature medicine



0

Eagerly awaited: RIC study, Kaiser Permanente California & Ontaria Health Insurance







| Country | Hospitals | Patients | Period |
|-------------|-----------|----------|-----------|
| UK | 91 | 322,125 | 1985-2013 |
| Netherlands | 42 | 148,135 | 1979-2015 |
| Sweden | 29 | 121,805 | 1977-2013 |
| France | 24 | 119,399 | 2000-2011 |
| Norway | 27 | 77,252 | 1980-2021 |
| Spain | 36 | 84,592 | 1991-2013 |
| Germany | 20 | 47,096 | 1983-2010 |
| Denmark | 6 | 17,696 | 1999-2014 |
| Belgium | 2 | 10,074 | 2000-2015 |
| Total | 278 | 948,174 | 1977-2015 |



**** * ** European Commission


Mean follow-up ~8 years

Bernier et al, Int J Epidemiol 2018

Organ dose estimation with NCICT



NCICT beta version 2.0 23 File Batch Help Dose (mGy) Patient parameters Brain 0,511 Age 0,348 5-year Pituitary gland 0,288 Lens Gender O Male Female Eye balls 0,323 Salivary glands 2,17 Height 111 Oral cavity 1,51 Spinal cord 11,094 Weight 19 23,785 Thyroid Esophagus 18,036 Trachea 21,75 Scanner parameters Thymus 23,021 22,485 Lungs Manufacturer Phillips • 18,943 Breast Heart wall 23,169 Model Aura • Stomach wall 9,507 Head filter O Body filter Liver 12,057 3,322 Gall bladder 24.6 nCTDIw (mGy/100mAs) Adrenals 11,183 Spleen 11,671 Pancreas 2,859 3,314 Kidnev Small intestine 0,728 1 Pitch Colon 0,738 Lee et al, Rectosigmoid 0,206 Tube potential (kVp) 120 Urinary bladder 0,134 **J** Radiol Prot Prostate Current x Time (mAs) 100 2015 Uterus 0,176 Testes CTDIvol (mGy) 24,6 0,219 Ovaries Skin SSDE (mGy) General protocol 4,379 Chest Muscle 5,087 DLP (mGycm) Bar Graph Active marrow 4,729 408 Scan End (cm) Scan Start (cm) Shallow marrow 7,469 8,598 22 38 ED60 Copy organ list to Clipboard ED103 9,829






Mean dose to the brain and the bone marrow per (head) CT by year

Brain cancer dose-response





Poisson regression stratified for sex/birth cohort/country, 5-year lag, 5-year exclusion Hauptmann et al, Lancet Oncol 2022



Relative risks by bone marrow dose

| Dose | Hematological malignancies | | | | | |
|-------------|----------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| categories | All | | Lymphoid | | Myeloid | |
| (mGy) | # | RR | # | RR | # | RR |
| [0,5) | 125 | 1.00 | 91 | 1.00 | 34 | 1.00 |
| [5,10) | 171 | 1.10 (0.87, 1.39) | 120 | 1.07 (0.81, 1.42) | 47 | 1.08 (0.69, 1.71) |
| [10,15) | 157 | 1.53 (1.20, 1.97) | 123 | 1.65 (1.24, 2.20) | 32 | 1.16 (0.70, 1.92) |
| [15,25) | 165 | 1.40 (1.09, 1.80) | 121 | 1.41 (1.05, 1.90) | 42 | 1.31 (0.80, 2.15) |
| [25,50) | 114 | 1.87 (1.42, 2.45) | 81 | 1.81 (1.32, 2.49) | 32 | 1.96 (1.17, 3.29) |
| [50+] | 58 | 2.66 (1.92, 3.70) | 42 | 2.64 (1.80, 3.89) | 16 | 2.75 (1.47, 5.14) |
| P for trend | | 0.022 | | 0.025 | | 0.02 |
| ERR/100 mGy | 1.96 (1.10, 3.12) | | 2.01 (1.02, 3.42) | | 2.02 (0.47, 4.77) | |
| (95% CI) | | | | | | |

Poisson regression stratified for sex/birth cohort/country, 2-year lag, 2-year exclusion, no evidence of non-linearity Bosch de Basea, Nat Med 2023

9

Interpretation of results

- Brain cancer results supported by Australian study
- Somewhat higher risks than a-bomb survivors (LSS*)

| | LSS | EPI-CT |
|--------------------|-------------------|-------------------|
| Brain | 0.61 (0.01, 6.39) | 1.27 (0.51, 2.69) |
| Leukemia excl. CLL | 0.77 (0.31, 1.2) | 1.66 (0.43, 3.74) |
| NHL | 0.88 (0.36, 3.6) | 2.51 (1.14, 4.73) |

- Strength: exposure events electronically recorded
- Major weakness: lack of data on indication
 → risk of indication bias & reverse causation
 - Slow growing tumors
 - Cancer susceptibility syndromes (CSS)
- Indirect evidence: indication bias & reverse causation unlikely to explain results

*Age at exposure<20 (35 NHL) yrs, follow-up<20 yrs after exposure

Clinical implications



- Per 10,000 children with 1 head CT (20 mGy), about 1 radiation-induced brain cancer expected in following decade
- Per 10,000 children with 1 CT (8 mGy), 1-2 radiation-induced hematological malignancies expected in following decade
- 3.3 million pediatric CTs per year in the US in 2023, including 1.6 million head CTs

Projected number of cancers caused

 US, 2023: 61,510,000 patients had 93,000,000 CT examinations (based on IMV Medical Information Division CT Market Outlook Report)

JAMA Internal Medicine | Original Investigation


Projected Lifetime Cancer Risks From Current Computed Tomography Imaging

Rebecca Smith-Bindman, MD; Philip W. Chu, MS; Hana Azman Firdaus, MPH; Carly Stewart, MHA; Matthew Malekhedayat, BS; Susan Alber, PhD; Wesley E. Bolch, PhD; Malini Mahendra, MD; Amy Berrington de González, DPhil; Diana L. Miglioretti, PhD

- Age & sex distribution from 120,000 CTs (0.1%) in the ACR National Radiology Data Registry 2016-2020: 2,570,000 (4.2%) children
- 103,000 radiation-induced cancers projected to result from 2023 CTs, including 9700 in children (leukemia 550, brain 440)
- CT-associated cancer may account for 5% of new cancer diagnoses annually
- Projections largely based on BEIR VII model (LSS data) from 2005



Dose reduction & CT reduction?





International dose variation 2015-2017

- 2 million adult CTs
- 151 institutions
- 7 countries
- 4-17-fold range

More (randomized) studies on effectiveness of CT and improved patient outcomes?

Smith-Bindman et al, BMJ 2019



Conclusions

- Strong dose-response for brain cancer and hematologic malignancies after pediatric CT
- Significant ERR down to <50 mGy, no threshold
- Confounding by indication unlikely (external evidence)
- Substantial number of brain cancers and hematological malignancies due CT-related radiation
- No empirical evidence yet for adult CT exposures or for other cancer sites, other diseases (cognition?)
- Longer follow-up needed to evaluate latency patters but unlikely due to UK privacy regulations



The Alliance for Radiation Safety in Pediatric Imaging

Upcoming: Risk of Pediatric and Adolescent Cancer Associated with Medical Imaging (RIC)

- North America (Kaiser Permanente) and Ontario
- Children exposed to diagnostic medical radiation in utero & during childhood

| | | RIC | EPI-CT | Australia |
|---------------|--------------------------|------------------------------|----------------------------------|-------------------------|
| | Fetal-exposure cohort | Childhood-exposure cohort | | |
| Children | 3,474,000 | 3,724,632 | 1,170,186 | 611,544 |
| Cancers | 6,606 | 6,358 | | |
| Leukemias | 2394 | 2,372 | | |
| Avg f-up (yr) | 10.8 | 9.7 | 9.3 | 13.5 |
| Exposed to CT | 17,370 | 219,753 | 1,170,186 344 leukemia | 611,544 246 leukemia |